Description

Overview

Retatrutide (LY3437943) is an investigational peptide designed to activate three metabolic hormone receptors: GLP-1, GIP, and glucagon. The research rationale is to combine incretin-related effects on appetite and glucose regulation with glucagon-receptor effects on energy expenditure and lipid metabolism. Phase 2 human studies have reported substantial changes in body weight and metabolic markers, and larger clinical-development programs have continued to evaluate obesity and metabolic disease. Retatrutide remains investigational and should not be described as an approved weight-loss medication.

How It Works

• GLP-1 receptor activity: Influences appetite, insulin secretion, glucagon regulation, and gastrointestinal signaling.
• GIP receptor activity: Adds a second incretin pathway involved in insulinotropic and metabolic signaling.
• Glucagon receptor activity: Investigated for effects on energy expenditure, hepatic lipid metabolism, and fuel utilization.

Research Areas

• Obesity research
• Type 2 diabetes research
• Liver-fat / metabolic liver research
• Cardiometabolic endpoints

Research / Study Context

• Phase 2 obesity trial: Randomized human research evaluated multiple dose groups over extended treatment and measured body weight, metabolic markers, and adverse events.
• Metabolic clinical studies: Additional trials have examined glycemic control and related metabolic outcomes.

Key Research Findings

• Phase 2 studies demonstrate strong pharmacologic effects on body-weight endpoints.
• Gastrointestinal adverse events are common in incretin-based clinical research.
• Long-term benefit-risk and regulatory status remain under investigation.

Related Research

• Tirzepatide
• Semaglutide
• Survodutide

Scientific Reference Starter Set

• Peptide Education Hub: Retatrutide profile
• PubMed search: retatrutide triple hormone receptor agonist obesity phase 2
• ClinicalTrials.gov search: retatrutide